Treatment of endometrial hyperplasia with a danazol-releasing intrauterine device: a prospective study

Yukoku Tamaoka, Hideki Orikasa, Yukari Sumi, Keiichi Sakakura, Kiyoshi Kamei, Midori Nagatani, M Nagatani, Sachiko Ezawa
Gynecologic and obstetric investigation · 2004 · vol. 58(1) , pp. 42–48 · doi:10.1159/000077882 · PMID:15087596 · W2091434157
Non-randomised trial OA: closed CC0 ⤵ 4 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This prospective study evaluated a danazol-releasing intrauterine device for endometrial hyperplasia, finding improvement in all patients with varied regression patterns and a 20% recurrence rate.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The purpose of the present study was to assess the effect of a danazol-releasing intrauterine device (D-IUD) in the treatment of endometrial hyperplasia. Twenty patients with endometrial hyperplasia including 14 with simple endometrial hyperplasia and 2 with complex endometrial hyperplasia (group A), and 4 with atypical endometrial hyperplasia (group B) were enrolled in the prospective study between August 1999 and December 2003. During and just after the treatment, improvement was seen in all patients. Simple or complex endometrial hyperplasia (group A) demonstrated regression to a normal secretory endometrium (38% of group A), pseudodecidual stromal change (31%) and glandular atrophy (25%), and miscellaneous change (inflammation, necrosis, etc.) (38%). Atypical hyperplasia (group B) demonstrated regression to a normal secretory endometrium (25% of group B), pseudodecidual stromal change (75%), glandular atrophy (50%) and miscellaneous change (granulation) (25%). In group A, 2 women conceived after completion of the treatment. The recurrence rate in patients with endometrial hyperplasia (groups A and B) in the follow- up was 20% and acceptable as compared with other studies. The pretreatment menstrual interval patterns of the patients were maintained peri- and post-treatment. These data indicate that D-IUD therapy might be a novel and effective method for the treatment of endometrial hyperplasia.

My notes (saved in your browser only)

MeSH descriptors

Danazol Endometrial Hyperplasia Estrogen Antagonists Adult Danazol Endometrial Hyperplasia Endometrial Hyperplasia Estrogen Antagonists Female Humans Menstruation Middle Aged Prospective Studies Recurrence Uterus Uterus

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (24)

Cited by (4)

Source provenance

openalex
last seen: 2026-05-11T06:10:27.824888+00:00
pubmed
last seen: 2026-10-08T21:02:29.018211+00:00
unpaywall
last seen: 2026-10-14T06:23:58.021457+00:00
License: CC0 · commercial use OK